Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MED403
- Development stage
- Preclinical
- Lead developer
- Medley Therapeutics
- Modality
- Gene Therapies
01
Overview
MED403 is a preclinical genetic medicine candidate developed by Medley Therapeutics (formerly YAP Therapeutics) for the treatment of peripheral artery disease (PAD). It utilizes a genetic medicine approach to target the YAP/Hippo signaling pathway, which is a critical regulator of organ size and tissue regeneration. By modulating this pathway, MED403 aims to activate the body's innate regenerative capabilities to induce or regenerate vascular tissue in patients suffering from PAD. The technology is part of a Genetic Medicine Platform licensed from the Baylor College of Medicine and the Texas Heart Institute, specifically designed to restore function in degenerative and ischemic conditions.
Beyond the preview
Go deeper on MED403.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MED403.